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Olmsted syndrome (OS) is a rare genodermatosis classically characterized by the combination of bilateral mutilating
transgredient palmoplantar keratoderma (PPK) and periorificial keratotic plaques, but which shows considerable clinical
heterogeneity. The disease starts usually at birth or in early childhood. About 73 cases have been reported worldwide.
OS is observed in both sexes, although male cases are more frequent. The most suggestive symptoms associate PPK
with pseudoainhum and periorificial keratotic plaques. Frequently associated features include hair and nail abnormalities,
leukokeratosis, corneal default and recurrent infections. Pain and itching are variable but can be severe. Most of reported
OS cases are sporadic, although familial cases with different mode of inheritance were also described. Mutations in
TRPV3 (Transient receptor potential vanilloid-3) gene have recently been identified as a cause of autosomal dominant
(gain-of-function mutations) or recessive OS. Mutations in MBTPS2 (membrane-bound transcription factor protease, site
2) gene were identified in a recessive X-linked form. The diagnosis relies mainly on clinical features associating severe
PPK and periorificial keratotic plaques, but can be challenging in patients with incomplete phenotype or atypical features.
OS has to be differentiated from other severe forms of PPK including Vohwinkel, Clouston, Papillon-Lefèvre or
Haim-Munk syndromes, Mal de Meleda, pachyonychia congenita, Tyrosinemia type II and acrodermatitis enteropathica.
When differential diagnoses are difficult to exclude, genetic studies are essential to search for a TRPV3 or MBTPS2
mutation. However, additional genes remain to be identified. No specific and satisfactory therapy is currently available for
OS. Current treatments of hyperkeratosis (mainly emollients, keratolytics, retinoids or corticosteroids), either topical or
systemic, are symptomatic and offer only temporary partial relief. Specific management of pain and itching is important
to reduce the morbidity of the disease. The disease is debilitating and progressive keratoderma and auto-amputation of
digits can prevent patients from grasping and walking, and confine them to a wheelchair. New therapeutic options are
therefore crucial and are expected from a better understanding of the disease mechanisms. The use of TRPV3
antagonists would represent such a targeted and potentially powerful strategy.
Keywords: Olmsted syndrome, Palmoplantar keratoderma, Periorificial keratotic plaques, Clinical heterogeneity, TRPV3,
MBTPS2Résumé
Le syndrome d’Olmsted (SO) est une génodermatose rare et sévère, classiquement caractérisée par une kératodermie
palmo-plantaire (KPP) bilatérale transgrédiente et mutilante associée à des plaques kératosiques périorificielles. Il existe une
grande hétérogénéité clinique. Des anomalies des cheveux et des ongles, une leukokératose, des anomalies de la cornée et
de fréquentes infections peuvent être associées. La douleur et le prurit sont variables, mais peuvent être sévères. La maladie
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débute généralement à la naissance ou pendant la petite enfance. Approximativement 73 cas ont été rapportés à travers le
monde. La maladie touche les deux genres. La plupart des cas sont sporadiques, bien que des cas familiaux avec différents
modes de transmission aient également été décrits. Des mutations du gène TRPV3 (Transient receptor potential vanilloid-3)
ont récemment été identifiées dans les formes autosomiques dominante (mutations gain-de-fonction) et récessive. Des
mutations du gène MBTPS2 (membrane-bound transcription factor protease, site 2) ont été rapportées dans une forme
récessive liée à l’X. Le diagnostic est essentiellement clinique, reposant sur l’association d’une KPP sévère et de kératoses
périorificielles ; mais il peut être difficile chez les patients ayant une présentation incomplète ou des symptômes atypiques.
Le SO doit être différencié des autres KPP sévères telles les syndromes de Vohwinkel, de Clouston, de Papillon-Lefèvre ou
de Haim-Munk, le Mal de Meleda, la pachyonychie congénitale, la tyrosinémie de type II et l’acrodermatite entéropathique.
Lorsque le diagnostic est difficile à établir, les études génétiques sont essentielles afin de rechercher une mutation des
gènes TRPV3 ou MBTPS2. Cependant, d’autres gènes restent à identifier. Il n’existe à ce jour pas de traitement spécifique du
SO. Les traitements actuels de l’hyperkératose comprennent essentiellement des émollients, kératolytiques, rétinoïdes et
corticoïdes, locaux ou systémiques. La prise en charge spécifique de la douleur et du prurit représente un aspect important
du traitement. La KPP massive et l’auto-amputation des doigts peuvent être très invalidants. Le développement de
nouveaux traitements est crucial et attendu d’une meilleure compréhension des mécanismes pathologiques de la maladie.
L’utilisation d’antagonistes de TRPV3 représenterait une nouvelle option thérapeutique prometteuse.Introduction
Olmsted syndrome (OS) is a rare genodermatosis belong-
ing to the heterogeneous group of palmoplantar kerato-
derma (PPK). OS shows marked clinical and genetic
heterogeneity. The aim of this article is to give an updated
review of clinical features, genetics, pathological mecha-




This review is based on a literature search using PubMed.
To identify all publications related to Olmsted syndrome
and summarize reported cases, a comprehensive search of
PubMed was performed for all studies published prior to
December 1, 2014, using the search terms “Olmsted syn-
drome”, “mutilating palmoplantar keratoderma” or “perior-
ificial keratoderma”. We then checked the bibliography of
each article to identify additional references. Altogether, 59
reports containing a total of 73 OS were identified from
1927 until December 1, 2014.
Review
Disease name and synonyms
Mutilating palmoplantar keratoderma with periorificial ker-
atotic plaques (ORPHA659, MIM #614594 and #300918)
Olmsted Syndrome (OS)
Palmoplantar and periorificial keratoderma
Definition
Olmsted syndrome is a rare keratinizing disorder charac-
terized by the combination of bilateral mutilating trans-
gredient palmoplantar keratoderma and periorificial
keratotic plaques. This syndrome was first described in
1927 by Olmsted [1]. Since that date, similar cases havebeen reported in the literature under the heading of
Olmsted syndrome.
Epidemiology
Olmsted syndrome is a rare genodermatosis. The preva-
lence of the syndrome is unknown. To date, about 73
cases have been reported in the literature (Table 1). Al-
though the number of cases is probably underestimated,
the prevalence is likely to be less then 1/1000000.
The disease seems to occur worldwide and is observed
in both sexes, although male cases (~63% of OS pa-
tients) have been predominantly reported (Table 1).
Clinical description
The classical clinical phenotype of OS consists of bilateral
mutilating palmoplantar keratoderma and periorificial ker-
atotic plaques. However, OS shows high clinical variability
and a wide range of inconsistent clinical manifestations
have been reported [36,44]. Other features associated with
this condition have been described subsequently and con-
tinue to be reported. Clinical manifestations described in
detail below are not specific for OS, they can be rarely ob-
served and can also vary in severity. In addition, some fea-
tures observed in OS patients may be fortuitous and not a
part of this syndrome. The disease starts usually at birth, in
neonatal period or in early childhood, when the child starts
to walk and grasp, and worsens over time. The disease has
a slow but progressive course.
Skin
Initially, the hallmarks for the diagnosis of OS are
bilateral mutilating palmoplantar keratoderma (Figure 1A)
associated with periorificial keratotic plaques (mouth, nose,
eyes, genital, anal, ears, navel) (Figure 1B) [1]. Indeed, pro-
gression of the keratoderma may lead to flexion deformities,
Table 1 Reported Olmsted syndrome cases in the literature
Reference Number of cases Sex Mutation
Olmsted, 1927 [1] 1 Male Not reported
Costa, 1962 [2] 1 ? Not reported
Keir, 1967 [3] 1 Female Not reported
Ruiz-Maldonado et al., 1972 [4] 1 Female Not reported
Michalowski, 1983 [5] 1 Male Not reported
Poulin et al., 1984 [6] 1 Male Not reported
Barnett et al., 1985 [7] 1 Male Not reported
Harms et al., 1985 [8] 1 Male Not reported
Rivers et al., 1985 [9] 4 (child, father, paternal aunt and
grandmother)
2 females, 2 males Not reported
Battini et al., 1989 [10] 1 Male Not reported
Georgii et al., 1989 [11] 1 Female Not reported
Atherton et al., 1990 [12] and Armstrong et al.,
1997 [13]
1 (son of case reported in Keir,
1967 [3])
Male Not reported
Judge et al., 1991 [14] 1 Male Not reported
Hausser et al., 1993 [15] 1 ? Not reported
Ueda et al., 1993 [16] and Yoshizaki et al., 2001 [17] 1 Male Not reported
Lucker et al., 1994 [18] 1 Male Not reported
Cambiaghi et al., 1995 [19] 2 (twins) Male Not reported
Kress et al., 1996 [20] and Raskin and Tu, 1997 [21] 1 Female Not reported
Dogra et al., 1997 [22] 1 Male Not reported
Frias-Iniesta et al., 1997 [23] 1 Male Not reported
Santos et al., 1997 [24] 1 Male Not reported
Sirka et al., 1999 [25] 1 Male Not reported
Larregue et al., 2000 [26] 2 Male Not reported
Fonseca et al., 2001 [27] 1 Female Not reported
Koch et al., 2001 [28] 1 Female Not reported
Requena et al., 2001 [29] 1 Male Not reported
Bergonse et al., 2003 [30] 2 Male Not reported
Dessureault et al., 2003 [31] 1 Female Not reported
Ogawa et al., 2003 [32] 1 Female LOR excluded
Batra and Shah, 2004 [33] 1 Male Not reported
Inamadar et al., 2004 [34] 1 Male Not reported
Al-Mutairi et al., 2005 [35] 1 Female Not reported
Mevorah et al., 2005 [36] and Eytan et al., 2014 [37] 1 Male TRPV3 p.Trp521Ser
Ziaaddini et al., 2006 [38] 1 Male Not reported
Ali et al., 2007 [39] 3 (2 brothers) 2 Males, 1 ? Not reported
Yaghoobi et al., 2007 [40] and Haghighi et al.,
2012 [41]
2 (uncle, nephew) Male MBTPS2 p.Phe464Ser
Bedard et al., 2008 [42] 2 Female Not reported
Kumar et al., 2008 [43] 1 Female Not reported
Tao et al., 2008 [44] 1 Male Not reported
Nofal et al., 2010 [45] 2 (sister) Female Not reported
Vosynioti et al., 2010 [46] 1 Male Not reported
Tharini et al., 2011 [47] 2 Female Not reported
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Table 1 Reported Olmsted syndrome cases in the literature (Continued)
Elise Tonoli et al., 2012 [48] 1 Female Not reported
Lai-Cheong et al., 2012 [49] 1 Male TRPV3 p.Gly573Ser
Lin et al., 2012 [50] 6 5 females, 1 male TRPV3 p.Gly573Ser (4 cases),
p.Gly573Cys (1 patient) and
p.Trp692Gly (1 case)
Tang et al., 2012 [51] 1 Male Not reported
Attia et al., 2013 [52] 1 Male Not reported
Danso-Abeam et al., 2013 [53] 1 Female TRPV3 p.Gly573Ala
Alotaibi et al., 2014 [54] 1 Male Not reported
Duchatelet et al., 2014a [55] 1 Female TRPV3 p.Leu673Phe
Duchatelet et al., 2014b [56] 2 (brother) Male TRPV3 p.Gly568Cys and
p.Gln216_Gly262del
He et al., 2014 [57] 2 (father and son) Male TRPV3 p.Gln580Pro
Kariminejad et al., 2014 [58] 1 Male TRPV3 p.Trp692Cys
Wang et al., 2014 [59] 1 Male MBTPS2 c.671-9 T > G
Total 73 26 Females, 44 Males 14 TRPV3 mutations
2 MBTPS2 mutations
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amputations. However, this pseudoainhum feature is in fact
inconsistently reported in OS patient [45]. In addition, in
rare cases, periorificial keratotic plaques are absent [55,56].
Keratoderma is initially focal and distributed on the pressure
points, gradually extends to most of the surface and be-
comes diffuse, massive and thicker with time with painful
deep fissures. The keratotic lesions are pruritic and can be
painful with pressure. Some cases present with focal or
punctuate keratoderma [45,57]. A clear improvement of the
keratoderma during febrile diseases may occur [19]. OtherFigure 1 Clinical features. A. Diffuse and transgredient, inflammatory
plantar keratosis in a 2 year of age child. B. Periauricular keratosis in a
2 year of age child.patients are reported with nonperiorificial keratotic lesions
involving the thighs, arms, elbows, knees and intertriginous
folds. Hyperkeratotic linear streaks [45,52], follicular kera-
tosis [40], pachyderma, cheilitis [47], ichthyotic lesions or
chronic blepharitis [14,23,40] may be also observed.
Pain and itching
Slight to severe pain with variable intensity is a frequent
feature of OS [6,9,18,36,44,45]. Painful PPK is reported
in around 50% of OS cases, it can be disabling causing
most of the time the patient to avoid walking and grasp-
ing. In the less severe patients, only slight pain not inter-
fering with hand and feet activities (walking, writing,
grasping objects) is mentioned [45].
Itch has also been reported, although less frequently
[36,44]. Pruritus, which can be severe, is mentioned in
around 16% of OS cases.
Thus, pain and itch represent major causes of morbid-
ity resulting in insomnia and interfering with walking
and grasping.
Atypical OS, with nonmutilating PPK and no periorifi-
cial keratotic plaques, associated with erythromelalgia is
rarely observed [55,56]. Pain and itching are reported to
be particularly severe in uncommon OS patients with
erythromelalgia which lead to acute flares of hyperalge-
sia, severe itch, erythema, vasodilatation and warmth of
the legs and extremities (hands, feet and ears) [55,56].
Erythromelalgia is triggered by heat and pain and is re-
duced by immersion in cold water. In these patients pre-
senting with dysesthesia (tingling or burning sensations)
and allodynia with increased sensitivity to thermal and
mechanical stimuli, the pain has clearly features of
neuropathic pain. The extend to which similar but less
Duchatelet and Hovnanian Orphanet Journal of Rare Diseases  (2015) 10:33 Page 5 of 10severe features could be present in other cases of OS re-
mains to be evaluated.
Hair and nails
The vast majority of patients present with hair abnormal-
ities including alopecia (diffuse, universal or patchy), hypo-
trichosis, sparse, thinning, curly, woolly, coarse, dry or
easily broken hair [22,36,44,47,51]. Microscopic Hair
examination may show pili torti, trichorrhexis nodosa type
defects, reduced pigment, as well as longitudinal ridges
and transverse fractures of the hair shaft [19,22,36]. Rare
OS cases have normal hair.
Sparse and thin eyebrows and eyelashes but also
madarosis are also reported [19,40]. In contrast, eyelash
trichomegaly is also observed in OS patients [56].
OS patients often show nails abnormalities including
dystrophic, lusterless, ridged, rough nails, hyperkeratosis,
onychogryphosis, leukonychia, irregular curvatures, ony-
cholysis, paronychia, subungual hyperkeratosis and even
absence of nails [22,32,36,43–45,60].
Oral cavity
Leukokeratosis of the tongue or buccal mucosa have
been noted [2,6,11,16,24,27,33,36].
Sweating
Sweating abnormalities such as palmoplantar hyperhi-
drosis or anhidrosis, acral hyperhidrosis are reported in
OS patients [29,61].
Eye
Eyes lesions are frequently described in OS patients, in-
cluding corneal dystrophy, epithelial dysplasia and opacity
[10,14,40]. Inflamed lacrimal glands/ducts or meibomian
glands dysfunction are also observed.
Growth
Delayed physical development leading to short stature is
frequently described in OS patient [32,36,59].
Recurrent infections
OS patients are prone to recurrent bacterial or candidal
infections in keratotic areas [11,14,20,26,27,30]. Periony-
chial infections are also mentioned.
Immunity
The immunological phenotype was assessed in one OS
patient and demonstrated immune dysregulation leading
to frequent dermal infections, inflammatory infiltrate in
the affected areas, hyper IgE production and elevated
follicular T cells and eosinophils in the peripheral blood
[53]. Immunodeficiency of an unknown origin has been
also reported in another patient [11].Predisposition to malignancies
OS patients may have a higher susceptibility to develop
malignant tumors in keratotic areas such as verrucous
carcinoma (a squamous cell carcinoma) and its variant
epithelioma cuniculatum located on the sole of the foot,
and malignant melanoma [7,15,17,31,32,62].
Teeth
Abnormal dentition with absence of premolar teeth [6],
mammiliations on the free margins of the incisors [34]
or peridontal disease leading to premature teeth loss
[54] are mentioned.
Hearing
Hearing loss for high frequencies and congenital deaf-
mutism are noted in few OS patients [6,11,29,48].
Bone
Deformed lower extremities (bow legs) as well as anky-
losis (knee and ankles joints), likely resulting from long-
term impeded mobility due to painful hyperkeratosis,
are described [51]. Osteoporosis and osteolysis of hands
and feet [2,3,6,24,26,32] have been also reported.
Other abnormalities
Other abnormalities including joint laxity [6,11,16,26],
primary sclerosing cholangitis [11], intellectual disability
[1,12] and haemangioma [35] are also rarely observed in
OS patients.
Thus, OS syndrome may result from multiple defects
in embryonic structures with a major ectodermal in-
volvement as found in ectodermal dysplasia, with pos-
sible minor mesodermal abnormality as manifested by
hyperlaxity of joints in some cases.
Aetiology
Genetics
Most reported OS cases are sporadic, although familial cases
with different modes of inheritance (dominant or recessive
autosomal or X-linked inheritance) were also reported.
Recently, the genetic basis has been partially elucidated
by the identification of mutations in TRPV3 (Transient re-
ceptor potential vanilloid-3) in 14 OS patients with differ-
ent genetic background (Chinese, Indian, Iranian, Arabic,
Caucasian) [37,49,50,53,55–58]. TRPV3 has been reported
as a thermosensible cation non selective channel, activated
by temperature and several chemical ligands, predomin-
ately expressed in keratinocytes, and in sensory neurons
[63,64]. TRPV3 is a transmembrane channel belonging to
the family of TRP (Transient receptor potential) [63,64]
and consists of 6 transmembrane domains with cytoplas-
mic N and C-termini, assembling as tetramers. TRPV3mu-
tations are responsible for autosomal dominant but also
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(p.Gly573Ser in 5 unrelated patients, p.Gly573Cys, p.
Gly573Ala, p.Gln580Pro, p.Leu673Phe, p.Trp692Gly and p.
Trp692Cys each in an unique case) have been reported
(Figure 2). Several dominant mutations were demonstrated
to be gain-of-function mutations leading to an increased
intracellular Ca2+ [50,57]. Three recessive mutations (p.
Trp521Ser in a homozygous state in one patient, and p.
Gly568Cys and p.Gln216-Gly262del in a compound het-
erozygote state in two brothers) were also reported
(Figure 2) [37,49,50,53,55–58]. Thus, the Gly573 residue,
and Trp692 to a lesser extent, are recurrently mutated. In
addition, all mutations, except for two recessive mutations,
are located in the S4-5 linker or in the C-terminal part of
the protein (Figure 2). The recessive p.Trp521Ser and p.
Gln216-Gly262del (resulting from the splicing site muta-
tion c.784 + 1G >A) mutations are located in the S2-3
linker and in the N-terminal part of the protein respect-
ively (Figure 2). OS caused by TRPV3 mutations shows
clinical heterogeneity. Indeed, OS patients with TRPV3
mutations present either with typical OS hallmarks or in-
complete phenotype with atypical features. Genotype-
phenotype correlations are difficult to establish at present
because of the few reported cases. However, the 5 patients
with the same p.Gly573Ser mutation present with a similar
phenotype including mutilating PPK with variable severity,
hair abnormalities (from dry hair to alopecia) and keratotic
plaques (periorificial or only in the natal cleft). In the other
hand, other mutations, located in the same part or in dif-
ferent domains of the protein, are associated with atypical
features (Figure 2). The p.Leu673Phe (dominant), p.
Gly568Cys (recessive) and p.Gln216-Gly526del (recessive)Figure 2 Schematic structure of TRPV3 and localization of reported O
mutations in green. Amino acids localized in the ARD (ankyrin repeats dom
pink and purple, respectively.mutations lead to atypical OS, with nonmutilating PPK
and no periorificial keratotic plaques, associated with ery-
thromelalgia [55,56]. The patient with the p.Gly573Ala pre-
sents with immune dysregulation [53]. The 2 related
patients with the p.Gln580Pro mutation have a very mild
phenotype with only focal PPK even at 37-year-old for the
father [57].
Mutations in MBTPS2 (membrane-bound transcription
factor protease, site 2) gene (p.Phe464Ser and c.671-9 T >
G), encoding a zinc metalloprotease essential for cholesterol
homeostasis and endoplasmic reticulum stress response,
have also been reported in recessive X-linked OS [41,59].
Mutations in MBTPS2 also lead to IFAP (Ichthyosis follicu-
laris - atrichia - photophobia) syndrome with or without
BRESHECK syndrome (MIM #308205, ORPHA2273) [65].
BRESHECK syndrome is a multiple congenital malforma-
tion characterized by intellectual disability, brain anomalies,
Hirschsprung disease, corneal opacifications, kidney dyspla-
sia, cryptorchidism, cleft palate, and skeletal malformations,
particularly of the vertebrae. The OS patient with the c.671-
9 T >G mutation also presents with classic IFAP syndrome
[59], whereas previously reported patients with the same
mutation in MBTPS2 has no OS features. The mechanism
by which MBTPS2 mutations lead to IFAP or OS is cur-
rently unclear.
There is no obvious clinical difference between OS
caused by TRPV3 and MBTPS2 mutations despite the
mode of inheritance. In addition, clinical variability is
observed even in patients from the same family or unre-
lated patients harbouring the same mutation, suggesting
the implication of modifier genes, epigenetics and/or en-
vironmental factors.S mutations. Dominant mutations are indicated in red and recessive
ain) and TRP (transient receptor potential) domains are indicated in
Table 2 Differential diagnosis and underlying molecular
basis
Disease Gene Mode of
inheritance
Vohwinkel syndrome GJB2, LOR Autosomal dominant
Mal de Meleda SLURP1 Autosomal recessive
Papillon-Lefèvre syndrome CTSC Autosomal recessive
Clouston syndrome GJB6 Autosomal dominant
Pachyonychia congenita KRT6A, KRT6B,
KRT16 and KRT17
Autosomal dominant
Tyrosinemia type II TAT Autosomal recessive
Haim-Munk syndrome CTSC Autosomal recessive
Acrodermatitis enteropathica SLC39A4 Autosomal recessive
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in either gene, indicating further genetic heterogeneity.
Pathogenesis
The pathogenesis of OS is poorly understood. However,
a defect in the expression of mature epidermal keratins
(1 and 10) and persistence of basal keratins (5 and 14)
was reported [20,21,27,45], as well as increased expres-
sion of Ki-67, a mitotic activity marker in basal and
suprabasal layers [29,44,48]. Thus, involved areas remain
in an immature state and continue to proliferate in an
improper fashion. This excessive epithelial proliferation
may result in hyperkeratosis. The mechanism by which
TRPV3 mutations lead to OS pathogenesis is unknown.
Functional studies of four TRPV3 mutations (p.Gly573-
Ser, p.Gly573Cys, p.Trp692Gly and p.Gln580Pro) using
patch clamp analysis on transfected HEK293 cells ex-
pressing TRPV3 mutants were performed [50,57]. These
studies have shown that these mutations lead to much
larger inward currents probably because of the constitu-
tive opening of the mutants [50]. Thus, these mutations
are gain-of-function mutations and result in elevated
intracellular Ca2+ inducing increased apoptosis, suggest-
ing that enhanced cell-death could drive OS [50]. In
addition, murine models have shown that TRPV3 is also
associated with TGF-α/EGFR signaling, which plays a
role in keratinocyte differentiation control [66]. Reported
immune dysregulation in OS suggests a primary (as
TRPV3 is expressed by Langerhans cells) or secondary
role of immunological processes in OS pathogenesis
[53]. Transcriptomic and proteomic investigation in pa-
tients with the p.Gln580Pro mutation, leading only to
focal PPK, showed decreased expression of proteins in-
volved in keratinocyte differentiation, in gap junction,
tight junction and desmosome formation, but increased
expression of proteins involved in keratinocyte prolifera-
tion and cell death [57]. Thus, the TRPV3 p.Gln580Pro
gain-of-function mutation disrupts the balance between
keratinocyte proliferation and differentiation, and com-
promises cell adhesion. In addition, previous studies on
murine models have also demonstrated that TRPV3 me-
diates release of pro-inflammatory cytokines including
interleukin IL-1α [67], an important mediator of cutane-
ous inflammation, but also prostaglandin E2 [68]. Of
note, TRPV3 is expressed in nociceptive neurons. Thus,
it is also likely that TRPV3 over-activation leads to local
overproduction of inflammatory cytokines which could
affect the somatosensory system, leading to a peripheral
neuropathic pain.
Diagnosis and diagnostic methods
Olmsted syndrome diagnosis relies on the clinical
presentation. Initially, the diagnostic hallmarks of OS are
the association of bilateral transgredient mutilatingpalmoplantar keratoderma and periorificial keratotic pla-
ques (mouth, nose, eyes, genital, anal, ears, navel) which al-
lows exclusion of other hyperkeratotic related disorders.
However, subsequent reports showed that this full-blown
OS is not always observed, making the diagnosis challen-
ging for patients with partial cutaneous expression of OS.
Unfortunately, the histopathology of skin sections shows
epidermal hyperplasia, orthohyperkeratosis, focal parakera-
tosis, hypergranulosis, acanthosis, and inflammatory infil-
tration in upper dermis, which are unspecific and of
limited use to orientate the diagnosis. In the absence of
specific biologic markers, molecular genetics is the most
powerful approach to establish the diagnosis when the clin-
ical presentation is unusual.Differential diagnosis
The diagnosis of Olmsted syndrome is supported by
clinical criteria that require the exclusion of other
diseases. OS has to be differentiated from other severe
forms of PPK, such as Vohwinkel syndrome (MIM#124500
and 604117, ORPHA494 and ORPHA79395), Mal
de Meleda (MIM#248300, ORPHA87503), Clouston
syndrome (MIM#129500, ORPHA189), Papillon-Lefèvre
syndrome (MIM#245000, ORPHA678), pachyonychia
congenita (MIM#167200 and 167210, ORPHA2309),
Tyrosinemia type II (MIM#276600, ORPHA28378) and
Haim-Munk syndrome (MIM#245010, ORPHA2342)
(Table 2) [52]. The periorificial involvement is the unique
characteristic of OS that allows exclusion of the above
syndromes. However, because of periorificial involvement,
OS is easily confused with acrodermatitis enteropathica
(MIM#201100, ORPHA37) which however can be ex-
cluded by measurement of zinc levels. Indeed, low plasma
level of zinc is diagnostic of acrodermatitis enteropathica
which shows improvement after oral zinc therapy, unlike
OS. Thus, the full-blown OS with its typical association of
mutilating bilateral PPK and periorificial keratotic plaques
is distinctive enough to lead to the correct diagnosis.
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tients with partial and moderate cutaneous expression
because of clinical overlap with other PPK mentioned
above. In this case, OS diagnosis should be considered
and molecular genetics and the mode of inheritance may
help to discriminate these disorders (Table 2). The diffi-
cult clinical and histopathological distinction between
different PPK makes genetic testing important in the
diagnostic approach to these patients.
Genetic counselling and antenatal diagnosis
Most reported OS cases are sporadic, although familial
cases were also reported. For familial cases, the mode of in-
heritance of OS has not been clearly established. Thus, dif-
ferent modes of inheritance have been suggested including
dominant or recessive autosomal pattern but also domin-
ant or recessive X-linked inheritance.
As with all severe genetic disorders, genetic counsel-
ling and psychological support are appropriate and re-
quested for the families, to discuss the aetiology, the
probability of occurrence in future pregnancies, the pos-
sibilities of early prenatal diagnosis and current treat-
ment available.
Management including treatment
There is currently no specific nor satisfactory treatment
for OS. Skin lesions are usually refractory to therapy.
Different treatments have been tried with varying suc-
cess to reduce hyperkeratosis. Topical treatments includ-
ing emollients (white petrolatum), keratolytics (urea,
salicylic acid), wet dressing, boric acid, tar, retinoid acid,
shale oil, corticosteroids, steroids are attempted with
poor to moderate improvement. In several OS patients,
systemic retinoids (acitretin, etretinate), corticosteroid or
methotrexate were used with poor to moderate relief
[9,15,16,51]. Repeated partial excision of palmoplantar
keratosis or full-thickness excision with skin grafting
have been also performed for few patients but was usu-
ally followed by recurrence of the hyperkeratosis after
initial improvement [42].
Until now, treatments either topical or systemic only offer
temporary partial symptomatic relief of pain and fissures by
reducing the thickness keratotic palmoplantar skin lesions.
Specific treatments of pain and itching are essential to reduce
the morbidity of the disease. Painkillers and topical lidocaine
can be effective, but for patients with severe pain and espe-
cially when erythromelalgia and/or neuropathic pain are
present, anti-inflammatory drugs, anticonvulsants (carba-
mazepine, gabapentin, pregabalin), tricyclic antidepressants
(amitriptyline, nortriptyline) and lastly opioid analgesics
(tramadol) are required to alleviate the pain of these patients.
Prolonged soaking of the affected parts in cold water may re-
duce pain. However, these treatments are ineffective in ar-
resting the course of the disease. The identification ofTRPV3 gain-of-function mutations indicates that TRPV3 an-
tagonists may be an effective therapeutic approach to treat
the OS patients harbouring such mutations.
Prognosis
The natural history of the disease can lead to severe mor-
bidities. Progressive keratoderma and auto-amputation of
digits worsens the disability by preventing patients from
grasping and walking, and can confine them to a wheel-
chair. Severe pruritus and pain increase the discomfort and
can result in insomnia. Corneal dystrophy can cause blind-
ness. In addition, OS patients may have a higher suscepti-
bility to develop tumors in keratotic areas. No reduced life
expectancy has been reported.
Unresolved questions
There have been recently many major advances in our
understanding of the genetic basis of OS, with the iden-
tification of TRPV3 and MBTPS2 mutations, although
other causal genes remain to be identified. Several ques-
tions remain unanswered with regards to the great vari-
ability of clinical expression of the disease, the lack of
phenotype/genotype correlation and the exact patho-
physiological mechanism(s) underlying OS. The broad
spectrum of OS clinical features raises the question
whether atypical reported cases really belong to OS. Mu-
tations within TRPV3 can cause both typical and atypical
OS cases. Thus, OS may be a heterogeneous syndrome
with variable clinical features.
Conclusion
For 87 years after its first description, around 73 OS cases
have been reported, increasing the spectrum of clinical fea-
tures associated with this condition and disclosing variable
clinical expression. OS diagnosis may be challenging in the
absence of the full-blown cutaneous phenotype associating
bilateral mutilating PPK and periorificial keratotic plaques.
The recent advances in the genetics of OS has lead to a
better understanding of the aetiology of the disease and
make possible the use of diagnostic genetic testing. Cur-
rently available drugs are nonspecific and poorly effective.
The identification of the molecular basis of OS will permit
the development of specific therapeutic strategies such as
TRPV3 antagonists, and better patient management. How-
ever, other genes remain to be identified and next gener-
ation sequencing is likely to permit to further elucidate the
genetics of OS and its clinical spectrum in patients with no
TRPV3 orMBTPS2 mutation.
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